| Literature DB >> 30096901 |
Hae-Soon Lim1, Ji-Eun Yeu2, Sang-Phil Hong3, Mi-Sun Kang4.
Abstract
Recently, studies have explored the use of probiotics like the Weissella cibaria strain, CMU (oraCMU), for use as preventive dental medicine instead of chemical oral care methods. The present study was conducted to investigate the antibacterial properties of the cell-free supernatant (CFS) from this bacterium. Cell morphology using the scanning electron microscope, and the antibacterial effect of CFS under various growth conditions were evaluated. The production of hydrogen peroxide, organic acids, fatty acids, and secretory proteins was also studied. Most of the antibacterial effects of oraCMU against periodontal pathogens were found to be acid- and hydrogen peroxide-dose-dependent effects. Lactic acid, acetic acid, and citric acid were the most common organic acids. Among the 37 fatty acids, only 0.02% of oleic acid (C18:1n-9, cis) was detected. Proteomic analysis of the oraCMU secretome identified a total of 19 secreted proteins, including N-acetylmuramidase. This protein may be a potential anti-microbial agent effective against Porphyromonas gingivalis.Entities:
Keywords: Weissella cibaria; antibacterial; cell-free supernatant; organic acid; probiotic; secretome
Mesh:
Substances:
Year: 2018 PMID: 30096901 PMCID: PMC6222630 DOI: 10.3390/molecules23081984
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Scanning electron microscopic (SEM) images of oraCMU at various magnifications: 5000× (a), 10,000× (b), 15,000× (c), 25,000× (d), 35,000× (e), and 45,000× (f).
Figure 2Dose-dependent effects of organic acid, hydrogen peroxide (H2O2), and a bacteriocin-like compound (BLC) in the cell-free supernatants (CFS) of oraCMU against periodontopathogenic bacteria. Optical density at 600 nm (OD600) of the cell suspension was measured. (a) Untreated CFS effect; (b) organic acid-dependent effect was measured using proteinase K and catalase-treated CFS; (c) H2O2-dependent effect was measured by the neutralized and proteinase K-treated CFS; (d) BLC-dependent effect was evaluated by the neutralized and catalase-treated CFS. P. gingivalis (●); Fusobacterium nucleatum (○); P. intermedia (▼).
Figure 3Growth and H2O2 production under various conditions. (a) Growth was monitored spectrophotometrically at 600 nm. (b) Production of H2O2, determined as mentioned in Section 4. Solid lines, aerobic incubation at 30 °C (●) and at 37 °C (○); broken lines, anaerobic incubation at 30 °C (▼) and at 37 °C (△).
Quantitative analysis of organic and fatty acids in the CFS of oraCMU after 16 h incubation at 37 °C.
| Acids | mg/mL | Acids | mg/mL | Acids | mg/mL |
|---|---|---|---|---|---|
| Oxalic acid | ND | Pentadecanoic acid (C15:0) | ND | ND | |
| Citric acid | 0.88 a | ND | ND | ||
| Succinic acid | ND b | Palmitic acid (C16:0) | 0.00 | ND | |
| Lactic acid | 6.42 | Palmitoleic acid (C16:1) | ND | ND | |
| Acetic acid | 2.78 | Heptadecanoic acid (C17:0) | ND | Arachidonic acid (C20:4n-6) | ND |
| Butyric acid (C4:0) | ND | ND | ND | ||
| Caproic acid (C6:0) | ND | Stearic acid (C18:0) | ND | Heneicosanoic acid (C21:0) | ND |
| Caprylic acid (C8:0) | ND | Elaidic acid (C18:1n-9, | ND | Behenic acid (C22:0) | ND |
| Capric acid (C10:0) | ND | Oleic acid (C18:1n-9, | 0.2 | Erucic acid (C22:1n-9) | ND |
| Undecanoic acid (C11:0) | ND | Linoleiaidic acid (C18:2n-6, | ND | ND | |
| Lauric acid (C12:0) | ND | Linoleic acid (C18:2n-6, | ND | ND | |
| Tridecanoic acid (C13:0) | ND | α-Linolenic acid (C18:3n-3) | ND | Tricosanoic acid (C23:0) | ND |
| Myristic acid (C14:0) | ND | γ-Linolenic acid (C18:3n-6) | ND | Lignoceric acid (C24:0) | ND |
| Myristoleic acid (C14:1) | ND | Arachidic acid (C20:0) | ND | Nervonic acid (C24:1) | ND |
a Data expressed as the mean. b ND: not detected.
Figure 42D-gel electrophoresis of secreted proteins in the CFS of oraCMU after 16 h incubation at 37 °C.
Secreted proteins identified in the CFS of oraCMU.
| Spot No. a | Protein Description b | Accession Number c | MW (kDa) | PI | Protein Score CI (%) d |
|---|---|---|---|---|---|
| 1a–e | Type 1 glyceraldehyde-3-phosphate dehydrogenase | WP_010369259 | 35.756 | 5.03 | 100.00 |
| 2a–c | WP_010373609 | 29.343 | 5.40 | 100.00 | |
| 3 | TIGR00266 family protein | WP_043941068 | 24.976 | 4.91 | 99.19 |
| 4a–f | Leukocyte elastase inhibitor | XP_003482167 | 42.658 | 6.13 | 100.00 |
| 5a–c | WP_010372268 | 33.942 | 4.75 | 100.00 | |
| 6a,b | Hypothetical protein | WP_043711225 | 23.526 | 5.60 | 99.99 |
| WP_063083480 | 23.318 | 5.04 | 100.00 | ||
| 7 | Aldo/keto reductase | WP_063083131 | 36.627 | 5.08 | 100.00 |
| 8a,b | Single-stranded DNA-binding protein | WP_056973096 | 17.991 | 4.99 | 100.00 |
| WP_043709699 | 15.326 | 5.17 | 99.99 | ||
| 9a,b | NAD-dependent glyceraldehyde-3-phosphate dehydrogenase | KKU03010 | 41.843 | 5.54 | 100.00 |
| 10 | WP_0432710743 | 42.715 | 5.17 | 100.00 | |
| 11 | BMP family ABC | WP_060655478 | 39.514 | 9.18 | 100.00 |
| 12 | Nucleoside-diphosphate kinase | WP_043710743 | 42.715 | 5.17 | 100.00 |
| 13 | Glyceraldehyde 3-phosphate reductase | WP_010370341 | 36.629 | 5.00 | 100.00 |
| 14 | 16S rRNA (cytosine(1402)- | WP_004044730 | 35.71 | 8.73 | 99.64 |
| 15 | HTH-type | WP_008787014 | 33.031 | 6.59 | 99.94 |
| 16 | 2,3-diphosphoglycerate-dependent phosphoglycerate mutase | WP_010371458 | 26.717 | 4.94 | 100.00 |
| 17 | Phosphocarrier protein HPr | WP_010370017 | 9.191 | 4.57 | 99.19 |
| 18 | PTS mannose | WP_043709678 | 35.417 | 4.97 | 100.00 |
| 19 | Zinc-dependent alcohol dehydrogenase | XP_003482167 | 42.658 | 6.13 | 99.99 |
a Spot numbers refer to the proteins labeled in Figure 4. b Protein description derived from the MASCOT software (www.matrixscience.com). c Information obtained from the NCBI database (www.ncbi.nih.gov). d CI, confidence interval.